Analysis of the key themes driving M&A activity reveals that immuno-oncology accounted for 6 pharmaceutical deals announced in Q3 2023, worth a total value of $535.7m. The $500m acquisition of Ferring International Center by Royalty Pharma Plc was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q3 2023 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, immuno-oncology-related deal activity decreased by 92% in Q3 2023 compared with the previous quarter’s total of $6.9bn and fell by 94% as compared to Q3 2022. Related deal volume decreased by 77% in Q3 2023 versus the previous quarter and was 60% lower than in Q3 2022.
The top-ranked financial advisors supporting these M&A deals in Q3 2023 were Centerview Partners; Guggenheim Partners; HC Wainwright with 3, 2, 2 deals respectively.
The top-ranked legal advisors supporting these M&A deals in Q3 2023 were Cooley; Goodwin Procter; Gibson, Dunn & Crutcher with 5, 5, 4 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2023 – Thematic Intelligence, buy the report here.